Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the re-scheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in
Brief that aims to inform discussions about stimulating more meaningful productivity in terms of pharmaceutical R&D. More specifically, it explores how R&D efforts can be steered to areas of unmet clinical needs and how efficiency in the R&D process can
The national dose banding tables are to be used by hospital trust pharmacy teams to ensure a standard approach to dose banding of chemotherapy across all hospital trusts.
This guidance on the dispensing of adrenaline auto-injectors (150microgram) has been developed for pharmacies and dispensing GP practices. This validation protocol has been developed to ensure consistent practice nationally and to prevent the need for any local re-interpretation.
House of Commons Health and Social Care Committee report that identifies that tackling antimicrobial resistance needs to be firmly established as a ‘top five policy priority’ for the government in order to help prevent the virtual loss of worldwide modern
This Q&A has been developed for pharmacies and dispensing GP practices about the EpiPen and EpiPen Junior Supply issue.
Experts in children’s allergies have developed the advice in this letter to support parents and guardians of children who use Epipen Junior 150mcg.
Evidence-based recommendations on burosumab (Crysvita) for X‑linked hypophosphataemia in children and young people. Burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. It recommends: Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as
During 2017, the prices of certain generic medicines purchased by community pharmacies for the NHS increased unexpectedly, affecting an unusually high number of medicines. Although the Department of Health & Social Care (the Department) and its arms-length bodies took action
Data on trends in antimicrobial resistance and decreased susceptibility in gonococcal infection in England and Wales provided by GRASP. Public Health England reports annually on drug resistance and decreased susceptibility in gonorrhoea in England and Wales and has twice provided data
This document details local actions to ensure aTIV is offered to individuals aged 65 years and over.
Updated policy document outlines the arrangements for funding of the use of cobicistat as a booster in treatment of HIV infection (all ages).
Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder. This guidance replaces NICE interventional procedures guidance on intravesical microwave
Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia
This report seeks to highlight best practice in relation to reducing pharmaceutical waste from local initiatives with the purpose of encouraging others to introduce similar initiatives where appropriate.
This guideline provides recommendations on the pharmacological management of adults with acute migraine, and prophylaxis for patients with episodic or chronic migraine or medication overuse headache. This guideline will be of interest to healthcare professionals in primary and secondary care,
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive